DOI: 10.1055/s-00023610

Drug Research


Marre M, Shaw J, Brändle M et al., LEAD-1 SU study group.
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

Diabet Med 2009;
26: 268-278

Download Bibliographical Data

Search in: